文献速递胸部肿瘤放疗

酪氨酸激酶抑制剂联合胸部放疗治疗癌基因突变非小细胞肺癌患者的疗效与安全性:一项Meta分析

Efficacy and safety of tyrosine kinase inhibitors with thoracic radiotherapy for patients with oncogene-mutated non-small cell lung cancer: a meta-analysis.
PubMed 文献 · Radiat Oncol · 2024-11-06

该Meta分析纳入12项研究共2936例癌基因突变非小细胞肺癌患者,比较酪氨酸激酶抑制剂(TKIs)联合胸部放疗与单用TKIs的疗效与安全性。结果显示联合治疗与更优的中位无进展生存期和中位总生存期相关,一线治疗亚组同样获益,总不良事件风险增加但严重不良事件无显著差异。

要点

  • TKIs联合胸部放疗较单用TKIs与更优的mPFS和mOS相关(HR 0.42和0.56)。
  • 一线TKIs联合胸部放疗亚组mPFS和OS均更优(HR 0.37和0.47)。
  • 联合治疗总不良事件风险增加(OR 1.17),但严重不良事件无显著差异(OR 1.06)。

核心结论

  • 与单用TKIs相比,TKIs联合胸部放疗与生存获益相关,尤其作为一线治疗选择时。
  • TKIs联合胸部放疗可能增加总不良事件风险,但未增加严重不良事件风险。
  • TKIs联合胸部放疗可能是癌基因突变NSCLC患者有前景的治疗方案。

研究设计与样本

  • 系统检索PubMed、EMBASE和Cochrane Library数据库。
  • 纳入比较TKIs联合放疗与单用TKIs在癌基因突变NSCLC患者中疗效与安全性的研究。
  • 共纳入12项研究、2936例患者,其中TKIs联合胸部放疗组823例,单用TKIs组2113例。
  • 结局指标为中位无进展生存期(mPFS)、中位总生存期(mOS)和不良事件发生率,并对一线TKIs联合放疗进行亚组分析。

主要发现

  • TKIs联合胸部放疗组较单用TKIs组mPFS更优(HR 0.42,95%CI 0.30-0.59,p<0.00001)。
  • TKIs联合胸部放疗组较单用TKIs组mOS更优(HR 0.56,95%CI 0.41-0.70,p<0.00001)。
  • 一线TKIs联合胸部放疗亚组mPFS更优(HR 0.37,95%CI 0.26-0.52,p<0.00001)。
  • 一线TKIs联合胸部放疗亚组OS更优(HR 0.47,95%CI 0.31-0.70,p=0.0002)。
  • 联合治疗组总不良事件风险增加(OR 1.17,95%CI 1.06-1.29,P=0.002),严重不良事件(≥3级)无显著差异(OR 1.06,95%CI 0.58-1.92,P=0.86)。

关键数值与推荐

  • 放射性不良事件总体发生率:放射性肺炎41.3%、放射性食管炎15.4%、放射性皮炎11.1%。
  • 严重放射性肺炎发生率为4.5%,严重放射性食管炎发生率为6.2%。

临床怎么用

  • 原文结论认为TKIs联合胸部放疗可能是癌基因突变NSCLC患者有前景的治疗方案,尤其作为一线治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tyrosine Kinase Inhibitors (TKIs) is an important therapy for patients with oncogene-mutated Non-Small Cell Lung Cancer (NSCLC). However, acquired resistance remains a major challenge. The efficacy of TKIs plus thoracic radiotherapy (RT) in oncogene-mutated NSCLC patients is uncertain. Therefore, we performed a meta-analysis to comprehensively evaluate the efficacy and safety of thoracic RT plus TKIs in oncogene-mutated NSCLC patients. METHODS: The following databases were searched for relevant studies: PubMed, EMBASE, and Cochrane Library. Studies comparing the efficacy and safety of TKIs plus RT with TKIs alone in oncogene-mutated NSCLC patients were included in this analysis. Outcomes were median progression-free survival (mPFS), median overall survival (mOS), and incidence of adverse events (AEs). This analysis performed a subgroup analysis of the efficacy of first-line TKIs in combination with RT. RESULTS: This meta-analysis included 12 studies with 2936 patients (n = 823 patients with TKIs plus thoracic RT, n = 2113 patients with TKIs alone). The results showed that patients who received treatment with TKIs plus thoracic RT were associated with superior mPFS and mOS than those who were treated with TKIs alone (hazard ratio [HR]: 0.42, 95% CI 0.30-0.59, p < 0.00001; HR: 0.56, 95% CI 0.41-0.70, p < 0.00001, respectively). Subgroup analyses showed that TKIs plus thoracic RT as first-line treatment was associated with better mPFS and OS (HR: 0.37, 95% CI 0.26-0.52, p < 0.00001; HR: 0.47, 95% CI 0.31-0.70, p = 0.0002, respectively). Although the combination of TKIs with thoracic RT was associated with an increased risk of total AEs (odds ratio [OR]: 1.17, 95% CI 1.06-1.29, P = 0.002), there was no significant difference in serious AEs (grade ≥ 3) (OR: 1.06, 95% CI 0.58-1.92, P = 0.86). The most frequently occurring radiation-related AEs were radiation pneumonitis, radiation esophagitis, and radiation dermatitis, with overall rates of 41.3%, 15.4%, and 11.1%, respectively. The incidence of severe radiation pneumonitis and radiation esophagitis was 4.5% and 6.2%, respectively. CONCLUSIONS: In comparison to TKIs alone, TKIs plus thoracic RT are associated with survival benefits, especially as a first-line treatment option. Although TKIs plus thoracic RT may increase the risk of total AEs, it did not increase the risk of severe AEs. Therefore, TKIs plus thoracic RT may be a promising therapeutic regimen for oncogene-mutated NSCLC patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Li W, Wu P, Liang Z, et al. Efficacy and safety of tyrosine kinase inhibitors with thoracic radiotherapy for patients with oncogene-mutated non-small cell lung cancer: a meta-analysis. Radiat Oncol. 2024. PMID: 39506792. doi:10.1186/s13014-024-02538-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。